Welcome to our dedicated page for Wellgistics Health SEC filings (Ticker: WGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wellgistics Health, Inc. (NASDAQ: WGRX) SEC filings page on Stock Titan brings together the company’s official disclosures to U.S. regulators, including current reports on Form 8-K, quarterly reports on Form 10-Q, and related exhibits. These documents provide detail on Wellgistics Health’s operations as a pharmacy physical and technology enabling health IT company that connects more than 6,500 pharmacies and over 200 manufacturers through wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services.
Through its filings, Wellgistics has reported material events such as the license agreement with DataVault AI Inc. for intellectual property used to develop its PharmacyChain™ manufacturer-to-patient blockchain-enabled smart contracts platform, sponsorship and licensing arrangements related to Dream Bowl 2026, and debt conversion agreements. Filings also describe the launch and positioning of the EinsteinRx™ pharmacy dispensing optimization AI platform, changes in independent registered public accounting firms, and the reporting of quarterly financial results.
Investors can also review an 8-K describing a Nasdaq notice regarding the company’s minimum bid price deficiency and the associated compliance period, which outlines potential implications for the continued listing of WGRX on The Nasdaq Capital Market. These regulatory documents offer insight into governance, capital structure, strategic partnerships, and risk factors referenced in the company’s public communications.
On Stock Titan, SEC filings for WGRX are supplemented with AI-powered summaries that highlight key terms, financial metrics, and business developments from lengthy documents. Users can quickly identify items related to licensing arrangements, sponsorship agreements, auditor changes, and listing compliance, while still having access to the full text as filed with the SEC. The page also provides convenient access to forms associated with insider and shareholder-related activity when available, helping users track how Wellgistics Health’s regulatory profile evolves over time.
Wellgistics Health, Inc. (WGRX) files an amended S-1 registration describing its proposed public offering, recent acquisition accounting, capital structure and historical results. The company discloses a consolidated net loss of $39,103,367 and a weighted average of 56,863,720 common shares, implying a reported net loss per share of $0.63 in the presented period. The pro forma capital table reflects the issuance and sale of 11,182,565 shares subsequent to June 30, 2025 and potential additional shares or pre-funded warrants in the offering.
The filing explains material transaction terms: a patent application titled “Method and Apparatus for Prescription Management” (filed July 26, 2022; submitted Sep 26, 2023), issuance of 3,999,335 restricted shares valued at $15,000,000 as acquisition consideration, and a note payable originally $15,000,000 that was amended to a principal of $17,500,000 with scheduled installments in 2026 and 2028. The company reports a net tangible book value per share before the offering of $(0.60) and names Colonial Stock Transfer Company as transfer agent. Major insider holdings disclosed include Brian Norton (10,990,247 shares; 13.04%) and Suren Ajjarapu (10,445,447 shares; 12.40%).
Wellgistics Health, Inc. (WGRX) files an amended S-1 registration describing its proposed public offering, recent acquisition accounting, capital structure and historical results. The company discloses a consolidated net loss of $39,103,367 and a weighted average of 56,863,720 common shares, implying a reported net loss per share of $0.63 in the presented period. The pro forma capital table reflects the issuance and sale of 11,182,565 shares subsequent to June 30, 2025 and potential additional shares or pre-funded warrants in the offering.
The filing explains material transaction terms: a patent application titled “Method and Apparatus for Prescription Management” (filed July 26, 2022; submitted Sep 26, 2023), issuance of 3,999,335 restricted shares valued at $15,000,000 as acquisition consideration, and a note payable originally $15,000,000 that was amended to a principal of $17,500,000 with scheduled installments in 2026 and 2028. The company reports a net tangible book value per share before the offering of $(0.60) and names Colonial Stock Transfer Company as transfer agent. Major insider holdings disclosed include Brian Norton (10,990,247 shares; 13.04%) and Suren Ajjarapu (10,445,447 shares; 12.40%).
Wellgistics Health, Inc. (WGRX) files an amended S-1 registration describing its proposed public offering, recent acquisition accounting, capital structure and historical results. The company discloses a consolidated net loss of $39,103,367 and a weighted average of 56,863,720 common shares, implying a reported net loss per share of $0.63 in the presented period. The pro forma capital table reflects the issuance and sale of 11,182,565 shares subsequent to June 30, 2025 and potential additional shares or pre-funded warrants in the offering.
The filing explains material transaction terms: a patent application titled “Method and Apparatus for Prescription Management” (filed July 26, 2022; submitted Sep 26, 2023), issuance of 3,999,335 restricted shares valued at $15,000,000 as acquisition consideration, and a note payable originally $15,000,000 that was amended to a principal of $17,500,000 with scheduled installments in 2026 and 2028. The company reports a net tangible book value per share before the offering of $(0.60) and names Colonial Stock Transfer Company as transfer agent. Major insider holdings disclosed include Brian Norton (10,990,247 shares; 13.04%) and Suren Ajjarapu (10,445,447 shares; 12.40%).
Wellgistics Health, Inc. filed a current report to share investor communications it is using at upcoming events. On September 5, 2025, the company issued a press release announcing that it will present at three business conferences during September 2025, and that release is furnished as Exhibit 99.1.
The company is also providing an updated corporate presentation and a fact sheet, furnished as Exhibits 99.2 and 99.3, which it plans to use at these conferences and in future meetings with prospective investors and strategic partners. These materials, dated September 8, 2025, have been posted to the company’s investor website.
The press release, presentation, and fact sheet are furnished rather than filed, so they are not subject to certain Exchange Act liabilities and are not automatically incorporated into other securities law filings. The company emphasizes that these materials contain forward-looking statements and refers readers to its Form 10‑K and subsequent Form 10‑Q filings for a detailed discussion of related risks.
Wellgistics Health, Inc. entered into a Business Loan and Security Agreement with Agile Capital Funding, LLC for a principal amount of $1,300,000. The Agile Loan is effective as of August 26, 2025, matures on April 8, 2026, carries an interest charge of $572,000 assuming timely payments, and is to be repaid in weekly installments of $58,500. A portion of the loan was used to satisfy previously outstanding obligations with Agile Capital Funding, and the company received approximately $500,000 in cash proceeds, which it plans to use for general working capital. The loan is secured by certain company assets not otherwise pledged in other arrangements.
Separately, the company issued a press release on August 27, 2025 announcing the introduction of a fully customizable artificial intelligence engine integrated into its tech and hub platform. This press release is furnished as an exhibit and includes forward-looking statements subject to risks described in the company’s SEC reports.
Wellgistics Health, Inc. files an amended S-1 showing a combined set of operations and pro forma adjustments tied to the acquisition of Wellgistics. The company reported a consolidated net loss of $39,103,367 in one presented period with a weighted average of 56,863,720 shares and reported net loss per share figures of $0.63 and $0.69 in related tables. The filing discloses an offering of common stock (shares unspecified in this excerpt) at an assumed public price tied to the Nasdaq closing price on a 2025 date and shows outstanding common shares of 72,881,535 issued and 63,144,817 outstanding as of June 30, 2025.
The company details material transaction terms from the Wellgistics acquisition including a $15,000,000 note payable due in three equal annual installments beginning February 14, 2026, and issuance of 3,999,335 restricted shares recognized at a fair value of $15,000,000 as equity consideration. A U.S. utility patent application titled “Method and Apparatus for Prescription Management” was filed (July 26, 2022; submitted Sept 26, 2023) covering the tech and hub platform. Financial tables show material operating losses, high general and administrative expenses, and pro forma adjustments to goodwill and intangible assets.
Wellgistics Health, Inc. filed a current report to furnish a press release announcing its financial results for the second fiscal quarter ended June 30, 2025. The release, dated August 20, 2025, is attached as Exhibit 99.1 and is incorporated by reference into the disclosure items describing the results and related information.
The company specifies that the press release and related disclosures are being furnished, not filed, so they are not subject to certain liability provisions under the Securities Exchange Act and are not automatically incorporated into other securities law filings.
Wellgistics Health, Inc. reported significant operating losses and liquidity strain for the period ending June 30, 2025. The company recorded a net loss of $39.1 million for the six months and $6.67 million for the three months, contributing to an accumulated deficit of $48.86 million. Net cash used in operating activities for the six months was $3.43 million, and the registrant disclosed that these factors raise substantial doubt about its ability to continue as a going concern. The company completed an IPO raising gross proceeds of $4.0 million (net approx. $3.1 million) and issued shares under an equity purchase agreement that was subsequently terminated on August 13, 2025. Debt and credit facilities remain significant, including a revolving line of credit balance of $3.98 million and seller notes with $5.0 million classified as current. Intangible assets and goodwill are material on the balance sheet (~$19.2 million and $16.2 million, respectively). The filing also discloses a customer concentration risk (~15% of revenue) and elevated stock-based compensation and restricted-share programs.
Wellgistics Health, Inc. reports two major corporate updates. The company terminated its equity purchase agreement with Hudson Global Ventures, which had allowed it to direct the investor to buy up to $50,000,000 of Wellgistics common stock, and states that it incurred no termination fees or penalties when it ended this financing arrangement.
The company also discloses that on August 8, 2025, President and director Prashant Patel resigned from both roles, with his employment agreement ending the same day. His resignation is described as not arising from any dispute or disagreement over operations, policies, or practices. Wellgistics further notes press releases announcing the launch of its XRP Implementation Program and the termination of the equity line facility.